secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001193125-23-242617
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen completes Reata acquisition; SKYCLARYS launch underway in U.S.
---------------------------------------------------------------------

- Acquired SKYCLARYS (omaveloxolone), first FDA-approved treatment for Friedreich's ataxia.
- Over 1,000 patient start forms submitted in the U.S. since launch; EU review ongoing.
- Deal expected slightly dilutive to Non-GAAP EPS in 2023, neutral in 2024, accretive from 2025.
- Biogen to update 2023 financial guidance with Q3 earnings release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000119312523242617/0001193125-23-242617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000119312523242617/d487087d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-242617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer